compound
bear
carbonyl
group
michael
acceptor
capabl
conjug
addit
also
known
michael
addit
simplest
best
michael
acceptor
carbonyl
compound
expos
unsatur
atom
exomethylen
keton
lacton
vinyl
keton
fragment
often
use
design
new
anticanc
drug
togeth
other
propiolamid
dimethylamino
figur
assur
irrevers
coval
bind
cystein
residu
specif
protein
may
modul
select
potenc
drug
candid
target
coval
modif
emerg
valid
approach
drug
discoveri
drug
candid
canertinib
approv
drug
afatinib
neratinib
osimertinib
inhibitor
human
epiderm
growth
factor
receptor
ibrutinib
tyrosin
kinas
inhibitor
comprehens
review
publish
jackson
et
al
give
overview
biolog
activ
applic
variou
michael
acceptor
michael
acceptor
explor
prodrug
strategi
cancer
cellspecif
target
review
publish
zhang
et
al
two
doxorubicin
prodrug
maleimid
moieti
describ
maleimid
compon
respons
bind
human
serum
albumin
drug
carrier
arriv
target
cancer
tissu
doxorubicin
releas
carrier
cleavag
hydrazon
glycosid
bond
acid
environ
cancer
cell
prodrug
demonstr
superior
anticanc
efficaci
parent
drug
michael
acceptor
present
class
drug
exampl
drug
entacapon
antiparkinson
dimethyl
fumar
antipsoriat
sinc
use
treatment
multipl
sclerosi
rupintivir
experiment
antivir
drug
human
rhinovirus
exemestan
cytostat
ethacryn
acid
diuret
carbonyl
group
also
motif
found
plant
microbi
metabolit
semisyntheticsynthet
deriv
mani
use
clinic
practic
still
evalu
clinic
trial
vernolepin
helenalin
curcumin
pyrrocidin
fumar
angel
acid
deriv
classifi
toxin
vernolepin
helenalin
sesquiterpen
exomethylen
lacton
respons
irrevers
dna
polymeras
inhibit
pyrrocidin
macrocycl
alkaloid
produc
endophyt
fungi
directli
bind
nacetyllcystein
methyl
ester
michaeltyp
addit
exert
antimicrobi
cytostat
effect
leukemia
cell
angel
acid
ester
ingenol
mebut
identifi
activ
compon
euphorbia
peplu
l
latex
sap
effect
human
nonmelanoma
skin
cancer
actin
keratosi
gel
formul
ingenol
mebut
recent
approv
treatment
actin
keratosi
fumar
acid
ester
use
manag
psoriasi
curcumin
symmetr
extract
curcuma
longa
l
tropic
southeast
asian
plant
use
spice
tradit
indian
medicin
current
open
clinic
trial
involv
curcumin
mainli
evalu
combin
curcumin
substanc
use
anticanc
therapi
paper
report
design
prepar
novel
michael
acceptor
fumar
acid
diamid
chosen
amid
less
electrophil
analog
ester
better
michael
acceptor
base
previou
find
one
amid
bond
achiev
termin
amino
group
primaquin
pq
halogenanilin
figur
share
conjug
ccco
system
benzen
ring
compound
similar
cinnam
acid
acid
deriv
well
take
literatur
data
account
previou
experi
pq
deriv
assum
design
compound
high
pharmacolog
potenti
report
synthesi
evalu
antimicrobi
activ
wide
spectrum
bacteria
fungi
virus
biofilm
erad
abil
final
cytostat
activ
sever
human
tumor
cell
line
paper
aim
prepar
biolog
evalu
new
michael
acceptor
asymmetr
diamid
fumar
acid
prove
signific
conjug
michael
system
activ
also
prepar
seri
analog
compound
without
doubl
bond
eg
seri
succindiamid
compound
reduc
deriv
etc
seri
compound
one
amid
bond
achiev
primari
amino
group
pq
one
select
halogenanilin
first
reaction
step
monoethyl
fumar
monomethyl
succin
coupl
pq
give
deriv
b
use
bi
dimethylamino
methylen
pyridinium
hexafluorophosph
hatu
coupl
reagent
along
n
ndiisopropylethylamin
diea
howev
transform
carboxyl
acid
chlorid
amid
pq
gave
better
yield
product
hydrolysi
b
lithium
hydroxid
afford
correspond
acid
b
coupl
halogenanilin
presenc
hatudiea
follow
anilin
use
scheme
show
synthet
pathway
lead
compound
new
compound
fulli
character
ms
ir
nmr
spectroscop
method
element
analys
spectral
data
consist
propos
structur
given
short
materi
method
detail
supplementari
materi
presenc
carbonyl
function
group
compound
indic
appear
strong
stretch
vibrat
band
ir
spectra
amid
amid
ii
pq
residu
show
characterist
signal
nmr
spectra
hydrogen
atom
occur
methoxi
group
hydrogen
attach
chiral
carbon
multiplet
methyl
group
appear
singlet
ppm
triplet
doublet
ppm
spectra
show
characterist
pq
signal
methoxi
group
ppm
correspond
signal
aromat
region
two
signal
carbonyl
group
fumardiamid
appear
ppm
succindiamid
ppm
two
succin
acid
carbon
appear
aliphat
region
fumar
acid
carbon
connect
doubl
bond
locat
high
ppm
group
compound
show
characterist
quartet
averag
j
hz
closest
catom
trifluoromethyl
quartet
ppm
j
hz
mfluorophenyl
deriv
show
doublet
ppm
pfluorophenyl
deriv
doublet
ppm
catom
bear
fluorin
similar
jcoupl
constant
hz
two
neighbour
catom
appear
ppm
averag
j
hz
catom
substitut
chloro
atom
appear
ppm
mcl
ppm
pcl
chemic
structur
new
compound
also
support
mass
spectroscopi
molecular
ion
peak
correspond
expect
rel
molecular
mass
obtain
compound
diamid
subject
silico
analysi
evalu
divers
set
compound
topolog
polar
surfac
area
tpsa
calcul
relev
druglik
properti
number
atom
molecular
weight
mw
partit
coeffici
log
p
hbond
donor
hbd
hbond
acceptor
hba
molecular
refract
mr
paramet
calcul
chemicalizeorg
program
present
tabl
compound
fulli
agreement
lipinski
gelovani
rule
prospect
small
molecular
drug
mw
log
p
number
hbond
donor
number
hbond
acceptor
tpsa
mr
within
rang
number
atom
although
f
f
highest
permit
rel
molecular
mass
antimicrobi
screen
assess
panel
gramposit
bacteria
pneumonia
mfbf
aureu
atcc
methicillinresist
aureu
mrsa
sa
sa
e
faecali
atcc
three
vancomycinresist
enterococci
vre
b
b
b
cereu
atcc
b
subtili
atcc
gramneg
speci
p
aeruginosa
atcc
e
coli
atcc
marcescen
atcc
p
mirabili
mfbf
baumannii
mfbf
enteritidi
mfbf
four
mycobacterium
strain
tuberculosi
smegmati
atcc
kansasii
dsm
marinum
camp
fungi
two
strain
c
albican
atcc
ccm
c
krusei
ccm
c
parapsilosi
ccm
brasiliensi
atcc
result
antimicrobi
screen
fumardiamid
present
tabl
result
inact
fumardiamid
succindiamid
shown
gener
gramposit
bacteria
especi
pneumonia
aureu
atcc
suscept
compound
b
activ
b
cereu
well
howev
gramneg
bacterium
baumannii
suscept
among
test
microorgan
compound
except
mfluoro
deriv
show
select
antimicrobi
activ
bacterium
strain
comparison
meta
para
deriv
eg
vs
b
c
vs
e
vs
f
reveal
case
psubstitut
deriv
activ
analog
mderiv
pchlorofumardiamid
show
signific
activ
three
bacteri
strain
aureu
pneumonia
baumannii
also
c
albican
atcc
minimum
inhibitori
concentr
mic
valu
rang
compound
togeth
pfluoro
fumardiamid
f
show
antitubercular
activ
marinum
f
activ
tuberculosi
well
test
suscept
differ
bacteri
yeast
strain
fumardiamid
succindiamid
determin
minimum
biofilm
erad
concentr
mbec
result
present
tabl
fumardiamid
much
activ
analog
succindiamid
activ
compound
two
microorgan
name
e
faecali
aureu
show
high
suscept
fumardiamid
e
coli
pneumonia
p
aeruginosa
suscept
five
six
fumardiamid
high
biofilm
erad
potenti
fumardiamid
might
explain
reaction
michael
acceptor
cystein
thiol
could
prevent
disulfid
bond
format
wellknown
fact
cystein
homeostasi
impact
biofilm
format
product
extracellular
matrix
compon
well
fold
stabil
extracytoplasm
protein
also
crucial
dental
plaqu
format
autolysi
extracellular
dna
releas
genet
compet
bacteriocin
product
stabil
outer
membran
porin
protein
compound
evalu
broad
varieti
viral
infect
includ
herp
simplex
virus
vaccinia
viru
human
coronaviru
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
yellow
fever
viru
fumardiamid
mchloro
mtrifluoromethyl
anilin
residu
name
show
signific
antivir
activ
sindbi
viru
punta
toro
viru
concentr
requir
reduc
virusinduc
cytopathogen
compound
also
activ
coxsacki
viru
howev
select
index
si
eg
minimum
cytotox
concentr
mcc
ratio
quit
low
cytotox
antivir
activ
fumardiamid
vero
cell
cultur
display
tabl
data
hel
human
erythroleukemia
cell
line
hela
cervic
carcinoma
cell
line
madindarbi
canin
kidney
cell
mdck
cultur
shown
well
data
inact
succindiamid
gain
insight
cytotox
newli
synthes
compound
cytostat
activ
evalu
vitro
panel
nine
differ
human
cancer
cell
line
repres
variou
solid
tumor
type
includ
pancreat
adenocarcinoma
chronic
myeloid
leukemia
colorect
carcinoma
lung
carcinoma
acut
lymphoblast
leukemia
acut
myeloid
leukemia
chronic
myeloid
leukemia
multipl
myeloma
nonhodgkin
lymphoma
succindiamid
complet
inact
free
fumardiamid
show
activ
toward
select
tumor
cell
line
tabl
fumardiamid
mfluoroanilin
moieti
show
cytostat
activ
test
cell
line
valu
lowest
concentr
result
growth
inhibit
cell
line
suscept
three
msubstitut
deriv
eg
valu
cell
line
also
suscept
compound
valu
respect
glutathion
gsh
import
compound
present
mammalian
cell
tripeptid
central
amino
acid
cystein
bear
thiol
group
scaveng
carcinogen
compound
conjug
addit
protect
oxid
damag
drug
develop
process
usual
evalu
michael
interact
final
step
research
studi
interact
fumarmid
gsh
fumardiamid
incub
gsh
ammonium
format
buffer
ph
contain
acetonitril
h
ms
analysi
confirm
consumpt
gsh
howev
rate
gsh
addit
slow
incomplet
react
monitor
period
see
support
materi
melt
point
determin
apparatu
barloworld
scientif
uk
open
capillari
uncorrect
ir
spectra
record
spectrum
one
ftir
perkinelm
uk
uvvi
spectra
lambda
doublebeam
spectrophotomet
perkinelm
uk
nmr
spectra
record
nmr
avanc
spectromet
bruker
germani
mhz
nuclei
respect
chemic
shift
report
part
per
million
ppm
rel
tetramethylsilan
dimethyl
sulfoxid
residu
peak
refer
nmr
spectra
ppm
coupl
constant
j
report
hertz
hz
mass
spectra
collect
hplcmsm
instrument
hplc
agil
technolog
seri
ms
agil
technolog
tripl
quad
use
electrospray
ioniz
posit
mode
element
analys
perform
chn
leco
analyz
leco
corpor
usa
compound
routin
check
thinlay
chromatographi
tlc
merck
silica
gel
glass
plate
use
appropri
solvent
system
spot
visual
shortwav
uv
light
iodin
vapour
column
chromatographi
perform
silica
gel
mm
chemic
solvent
analyt
grade
purchas
commerci
sourc
pq
diphosph
acid
monomethyl
succin
e
acid
monoethyl
fumar
diea
hatu
purchas
sigmaaldrich
pq
prepar
pq
diphosph
prior
use
reaction
pq
run
light
protect
pqsuccinamid
fumaramid
monoest
b
prepar
condens
pq
base
monomethyl
succin
monoethyl
fumar
follow
previous
describ
procedur
carboxyl
acid
b
prepar
hydrolysi
ester
b
lithium
hydroxid
follow
previous
describ
procedur
solut
mmol
g
mmol
diea
g
mmol
hatu
ml
dichloromethan
stir
room
temperatur
min
mmol
correspond
halogenanilin
ad
reaction
mixtur
stir
h
room
temperatur
evapor
reduc
pressur
dissolv
ml
ethyl
acet
extract
time
water
organ
layer
dri
sodium
sulfat
filter
evapor
reduc
pressur
n
amino
pentyl
reaction
g
acid
g
mmol
purif
column
chromatographi
mobil
phase
dichloromethanemethanol
crystal
ether
g
obtain
mp
ir
atr
nmr
dd
j
j
dd
j
j
j
j
j
j
nmr
j
j
j
j
msm
mz
anal
calcd
c
h
n
found
c
h
n
n
amino
pentyl
reaction
g
acid
g
mmol
purif
column
chromatographi
mobil
phase
dichloromethanemethanol
crystal
ether
g
obtain
mp
ir
atr
nmr
dd
j
j
dd
j
dd
j
j
j
j
j
j
j
nmr
j
j
j
msm
mz
anal
calcd
c
h
n
found
c
h
n
n
amino
pentyl
reaction
g
acid
g
mmol
purif
column
chromatographi
mobil
phase
dichloromethanemethanol
crystal
ether
g
obtain
mp
ir
atr
nmr
dd
j
j
dd
j
j
h
j
dd
j
j
q
j
j
j
j
j
nmr
msm
mz
anal
calcd
c
h
n
found
c
h
n
n
amino
pentyl
reaction
g
acid
g
mmol
purif
column
chromatographi
mobil
phase
cyclohexaneethyl
acetatemethanol
crystal
ether
g
obtain
mp
ir
atr
nmr
dd
j
j
dd
j
j
j
j
j
nmr
msm
mz
anal
calcd
c
h
n
found
c
h
n
amino
pentyl
n
trifluoromethyl
phenyl
reaction
g
acid
g
mmol
purif
column
chromatographi
mobil
phase
dichloromethanemethanol
crystal
acetonewat
g
obtain
mp
ir
atr
nmr
dd
j
j
q
j
j
j
j
j
nmr
q
j
q
j
msm
mz
anal
calcd
c
h
n
found
c
h
n
amino
pentyl
n
trifluoromethyl
phenyl
reaction
g
acid
g
mmol
crystal
ether
g
obtain
mp
ir
atr
nmr
j
j
j
j
q
j
j
j
j
dd
j
j
j
nmr
q
j
q
j
q
j
msm
mz
anal
calcd
c
h
n
found
c
h
n
n
amino
pentyl
butanediamid
reaction
g
acid
g
mmol
purif
column
chromatographi
mobil
phase
dichloromethanemethanol
g
obtain
mp
ir
atr
nmr
dd
j
dd
j
j
j
j
j
j
j
j
nmr
j
j
j
j
msm
mz
anal
calcd
c
h
n
found
c
h
n
n
amino
pentyl
butanediamid
reaction
g
acid
g
mmol
purif
column
chromatographi
mobil
phase
dichloromethanemethanol
crystal
ether
g
obtain
mp
ir
atr
nmr
dd
j
dd
j
j
j
j
j
j
j
j
nmr
j
j
j
msm
mz
anal
calcd
c
h
n
found
c
h
n
n
amino
pentyl
butanediamid
reaction
g
acid
g
mmol
purif
column
chromatographi
mobil
phase
cyclohexaneethyl
acetatemethanol
crystal
ether
g
obtain
mp
ir
atr
nmr
dd
j
dd
j
j
j
j
j
j
j
j
j
nmr
msm
mz
anal
calcd
c
h
n
found
c
h
n
n
amino
pentyl
butanediamid
reaction
g
acid
g
mmol
purif
column
chromatographi
mobil
phase
dichloromethanemethanol
crystal
ether
g
obtain
mp
ir
atr
nmr
dd
j
dd
j
j
j
j
j
j
bs
j
j
j
nmr
msm
mz
anal
calcd
c
h
n
found
c
h
n
amino
pentyl
n
trifluoromethyl
phenyl
butanediamid
reaction
g
acid
g
mmol
purif
column
chromatographi
mobil
phase
dichloromethanemethanol
crystal
ether
g
obtain
mp
ir
atr
nmr
dd
j
dd
j
j
j
j
j
j
j
j
j
j
j
nmr
q
j
q
j
msm
mz
anal
calcd
c
h
n
found
c
h
n
amino
pentyl
n
trifluoromethyl
phenyl
butanediamid
reaction
g
acid
g
mmol
purif
column
chromatographi
mobil
phase
dichloromethanemethanol
g
obtain
mp
ir
atr
nmr
dd
j
dd
j
j
j
j
j
j
j
j
j
j
nmr
q
j
q
j
msm
mz
anal
calcd
c
h
n
found
c
h
n
staphylococci
enterococci
synthes
compound
evalu
vitro
antibacteri
activ
repres
multidrugresist
bacteria
clinic
isol
methicillinresist
staphylococcu
aureu
mrsa
sa
sa
obtain
nation
institut
public
health
pragu
czech
republ
aureu
atcc
use
refer
qualiti
control
strain
addit
compound
test
activ
vancomycinsuscept
enterococcu
faecali
atcc
refer
strain
three
isol
american
crow
vanacarri
vancomycinresist
e
faecali
vre
ampicillin
amp
ciprofloxacin
cip
sigmaaldrich
st
loui
mo
usa
use
standard
prior
test
strain
passag
onto
nutrient
agar
oxoid
basingstok
uk
bovin
blood
bacteri
inocula
prepar
suspend
small
portion
bacteri
coloni
steril
phosphatebuff
salin
ph
cell
densiti
adjust
mcfarland
unit
use
densitomet
densilamet
liap
riga
latvia
inoculum
dilut
reach
final
concentr
bacteri
cell
cfuml
well
compound
dissolv
dmso
sigmaaldrich
st
loui
mo
usa
final
concentr
dmso
cation
adjust
muellerhinton
camh
broth
oxoid
staphylococci
brainheart
infus
enterococci
exceed
total
solut
composit
final
concentr
evalu
compound
rang
broth
dilut
micromethod
modifi
accord
nccl
nation
committe
clinic
laboratori
standard
guidelin
mh
broth
staphylococcu
strain
camh
enterococcu
strain
use
determin
mic
drugfre
control
steril
control
control
consist
mh
camh
broth
dmso
alon
includ
determin
result
perform
visual
h
static
incub
dark
aerob
atmospher
b
gramposit
streptococcu
pneumonia
mfbf
bacillu
cereu
atcc
bacillu
subtili
atcc
gramneg
bacteria
speci
pseudomona
aeruginosa
atcc
escherichia
coli
atcc
serratia
marcescen
atcc
proteu
mirabili
mfbf
acinetobact
baumannii
mfbf
salmonella
enteritidi
mfbf
serial
microdilut
broth
assay
use
determin
mic
compound
cell
suspens
prepar
stock
cultur
use
phosphatebuff
salin
pb
gibco
laboratori
usa
ph
adjust
mcfarland
unit
use
nephelomet
atb
franc
stock
solut
test
compound
prepar
dmso
mgml
test
perform
use
serial
dilut
microtit
flatbottom
plate
compound
rang
inocul
cfuml
incub
h
aerob
dark
mic
bacteri
speci
determin
addit
mgml
ttc
chlorid
absorb
record
nm
posit
qualiti
control
suscept
strain
tetracyclin
hydrochlorid
tc
sigmaaldrich
ad
well
mic
determin
nonlinear
regress
use
graphpad
prism
lowest
concentr
result
growth
inhibit
growth
comparison
control
c
mycobacteria
mycobacterium
tuberculosi
atcc
grown
middlebrook
broth
mb
supplement
oleicalbumindextrosecatalas
oadc
supplement
difco
lawrenc
ks
usa
mycobactin
j
log
phase
growth
cultur
sampl
ml
centrifug
min
use
benchtop
centrifug
mpw
med
instrument
poland
follow
remov
supernat
pellet
wash
fresh
middlebrook
broth
resuspend
fresh
odacsuppl
mb
ml
turbid
adjust
match
mcfarland
standard
cfu
mb
broth
dilut
cultur
perform
mb
broth
antimicrobi
suscept
tuberculosi
investig
plate
format
experi
steril
deionis
water
ad
outerperimet
well
plate
minim
evapor
medium
test
well
incub
evalu
compound
incub
tuberculosi
dilut
compound
prepar
duplic
synthes
compound
final
concentr
rang
compound
dissolv
dmso
subsequ
dilut
made
supplement
mb
plate
seal
parafilm
incub
day
follow
incub
alamarblu
difco
lawrenc
ks
usa
mix
well
read
nm
nm
taken
initi
background
subtract
subsequ
h
reincub
background
subtract
necessari
strongli
colour
compound
colour
may
interfer
interpret
colour
chang
noninterf
compound
blue
colour
well
interpret
absenc
growth
pink
colour
score
growth
evalu
vitro
antimycobacteri
activ
compound
addit
perform
smegmati
atcc
marinum
camp
kansasii
dsm
broth
dilut
micromethod
middlebrook
medium
difco
lawrenc
ks
usa
supplement
adc
enrich
becton
dickinson
comp
use
determin
mic
previous
describ
compound
dissolv
dmso
sigmaaldrich
final
concentr
dmso
exceed
total
solut
composit
final
concentr
evalu
compound
rang
obtain
twofold
serial
dilut
stock
solut
microtit
plate
steril
medium
bacteri
inocula
prepar
transfer
coloni
cultur
steril
water
cell
densiti
adjust
mcfarland
unit
use
densitomet
densilamet
liap
riga
latvia
final
inoculum
made
dilut
suspens
steril
water
drugfre
control
steril
control
control
consist
medium
dmso
sigmaaldrich
st
loui
mo
usa
alon
includ
determin
result
perform
visual
day
static
incub
dark
aerob
atmospher
smegmati
day
static
incub
dark
aerob
atmospher
kansasii
day
static
incub
dark
aerob
atmospher
marinum
ciprofloxacin
cip
rifampicin
rif
isoniazid
inh
sigmaaldrich
st
loui
mo
usa
use
standard
microdilut
method
use
test
antifung
activ
newli
synthes
compound
candida
albican
ccm
atcc
c
krusei
ccm
c
parapsilosi
ccm
czech
collect
microorgan
brno
czech
republ
test
compound
dilut
sigma
broth
concentr
flucytosin
flu
sigma
amphotericin
b
amph
use
posit
control
plate
inocul
inoculum
prepar
broth
final
concentr
fungal
cell
cfuml
well
plate
incub
c
albican
c
krusei
c
parapsilosi
hour
drugfre
control
includ
mic
defin
greater
reduct
growth
comparison
control
mic
determin
aspergillu
brasiliensi
perform
rpmi
broth
glutamin
supplement
glucos
follow
scheme
bacteria
procedur
b
incub
period
h
aerob
dark
xtt
phenylamino
carbonyl
hydroxid
mgml
combin
menadion
mgml
aceton
vv
ad
absorb
read
nm
amph
use
posit
control
solvent
media
microorgan
ad
neg
control
biofilm
erad
screen
perform
follow
microorgan
aureu
atcc
pneumonia
mfbf
e
faecali
atcc
b
cereu
atcc
b
subtili
atcc
e
coli
atcc
p
aeruginosa
atcc
marcescen
atcc
p
mirabili
mfbf
enteritidi
mfbf
baumannii
mfbf
c
albican
atcc
mbec
fumardiamid
succindiamid
determin
follow
well
plate
fill
bacteri
cfuml
yeast
cfuml
suspens
inhibit
yeast
biofilm
format
test
well
pretreat
fetal
bovin
serum
fb
per
well
neg
control
contain
broth
posit
control
perform
use
standard
antimicrobi
drug
gentamycin
gen
amph
respect
plate
cover
incub
aerob
h
bacteria
h
yeast
follow
incub
period
well
aspir
wash
three
time
vigor
shaken
remov
nonadher
bacteriayeast
remain
attach
cell
fix
methanol
min
plate
left
dri
overnight
form
biofilm
stain
crystal
violet
min
excess
stain
rins
place
plate
run
tap
water
plate
left
dri
adher
cell
solubil
use
ethanol
absorb
read
nm
mbec
valu
repres
lowest
dilut
compound
bacteria
fail
grow
antivir
activ
compound
determin
describ
previous
cytotox
antivir
activ
assay
toward
herp
simplex
viru
hsv
strain
ko
g
tkko
acvr
vaccinia
viru
human
coronaviru
hel
cell
cultur
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
hela
cell
cultur
viru
sindbi
coxsacki
viru
punta
toro
viru
yellow
fever
viru
vero
cell
cultur
influenza
influenza
influenza
b
virus
madindarbi
canin
kidney
mdck
cell
cultur
perform
day
infect
growth
medium
aspir
replac
serial
dilut
test
compound
viru
ad
well
dilut
obtain
viral
input
viru
dose
abl
infect
cell
cultur
mocktreat
cell
cultur
receiv
sole
test
compound
includ
determin
cellular
cytotox
day
incub
virusinduc
cytopath
determin
visual
score
cytopath
effect
cpe
light
microscop
evalu
virusinduc
cpe
inhibit
evalu
compound
well
measur
cell
viabil
colorimetr
formazanbas
mt
assay
experi
perform
duplic
antivir
activ
express
activ
compar
activ
parent
drug
pq
dextran
sulfat
approx
mw
standard
antivir
drug
ribavirin
rib
mycophenol
acid
mpa
brivudin
cidofovir
acyclovir
gancyclovir
zalcitabin
alovudin
uda
zanamivir
amantadin
rimantadin
cytostat
activ
evalu
vitro
nine
differ
type
human
tumor
cell
line
well
hematolog
tumor
describ
previous
human
tumor
cell
line
acquir
american
type
cultur
collect
atcc
manassa
va
usa
except
cell
line
purchas
deutsch
sammlung
von
mikroorganismen
und
zellkulturen
dsmz
leibnizinstitut
braunschweig
germani
cell
line
purchas
horizon
discoveri
waterbeach
uk
cultur
modifi
medium
imdm
gibco
life
technolog
gaithersburg
md
usa
grown
medium
gibco
life
technolog
cultur
rpmi
gibco
life
technolog
media
supplement
fb
hyclon
ge
healthcar
life
scienc
usa
adher
cell
line
cell
seed
densiti
cell
per
well
blackwal
clearbottom
tissu
cultur
plate
greiner
bioon
germani
overnight
incub
cell
treat
test
compound
four
differ
concentr
rang
suspens
cell
line
seed
densiti
rang
cell
per
well
blackwal
clearbottom
tissu
cultur
plate
contain
test
compound
four
concentr
plate
incub
monitor
h
incucyt
essen
bioscienc
inc
ann
arbor
mi
usa
realtim
imag
imag
taken
everi
h
one
field
imag
per
well
magnif
compound
test
duplic
data
point
averag
activ
compar
activ
parent
drug
pq
standard
anticanc
drug
docetaxel
dxt
etoposid
epeg
staurosporin
st
fumardiamid
incub
gsh
ammonium
format
buffer
ph
contain
acetonitril
h
progress
reaction
monitor
percent
remain
fumardiamid
determin
ms
use
intern
standard
n
benzyloxi
amino
pentyl
butanediamid
aliquot
reaction
mixtur
taken
h
analys
synapt
esiqtofm
system
water
milford
usa
aliquot
dilut
time
acetonitril
spray
flow
rate
use
fluidic
system
instrument
ms
condit
set
follow
posit
ion
mode
capillari
voltag
kv
sampl
cone
voltag
v
sourc
temperatur
desolv
temperatur
desolv
ga
flow
lh
mass
spectra
record
mz
frequenc
hz
data
acquir
analys
water
masslynx
softwar
twelv
novel
pqderiv
diamid
type
design
synthes
compound
differ
type
spacer
andor
halogen
atom
anilin
region
compound
fumardiamid
succindiamid
compound
b
b
fluoro
chloro
f
f
trifluoroderiv
new
compound
screen
antibacteri
antitubercular
antivir
cytostat
activ
well
biofilm
erad
abil
biolog
assay
fumardiamid
superior
succindiamid
indic
doubl
bond
conjug
carbonyl
import
activ
high
bioactiv
low
cytotox
conveni
druglik
properti
psubstitut
deriv
f
provid
strong
basi
research
optim
novel
agent
use
treatment
bacteri
biofilmassoci
infect
msubstitut
deriv
c
e
could
potenti
lead
develop
antitumor
agent
